Imiquimod for Cervical Dysplasia

A nonsurgical option for some women with CIN2 or CIN3

A LEEP is highly effective treatment for cervical dysplasia.

But it is not the only option worth discussing for every patient.

Imiquimod is an immune-response medication that has been studied as a nonsurgical treatment for high-grade cervical dysplasia. For appropriately selected women—particularly those who strongly prefer to avoid removing cervical tissue—it may offer another path to consider.

The decision depends on your pathology, cervical examination, previous history, future pregnancy goals, and how you weigh the benefits and limitations of each approach.

Imiquimod Treatment Program — $2,200 + applicable pathology fees

No Hitchcock Family Medicine membership required.

Get More Information

What is imiquimod?

Imiquimod is a medication that stimulates the local immune response.

Rather than removing abnormal cervical tissue, the goal is to help the immune system recognize and respond to HPV-associated abnormal cells.

Imiquimod is FDA-approved for several other conditions. Its use for cervical dysplasia is off-label, meaning cervical dysplasia is not specifically included in its FDA-approved labeling.

Its use on the cervix has nevertheless been studied in randomized clinical trials and systematic reviews, with regression of CIN2 and CIN3 demonstrated in a meaningful proportion of treated patients.

LEEP and other excisional procedures remain the standard treatment when high-grade cervical dysplasia requires treatment.

For the right patient, however, imiquimod can be a reasonable alternative to discuss.

Why might someone consider imiquimod?
PRESERVE CERVICAL TISSUE
Treatment without removing part of the cervix
LEEP works by removing the abnormal transformation zone. Imiquimod takes a different approach. No portion of the cervix is removed during treatment. For women concerned about preserving cervical tissue—particularly those thinking about future pregnancy—that difference may matter.
ANOTHER OPTION
Not wanting a LEEP is worth discussing
Some women come to us because they have been told they need a LEEP but would strongly prefer to avoid one if there is another medically reasonable option. That preference matters. It does not automatically mean imiquimod is appropriate, but it is a legitimate reason to have a thoughtful conversation about alternatives.
A DIFFERENT TRADEOFF
Less invasive does not mean more effective
LEEP has a higher treatment-success rate overall. Imiquimod offers the possibility of treating dysplasia without excision, but with a greater chance that the dysplasia will persist and additional treatment may ultimately be needed. The right choice depends partly on which tradeoffs matter most to you.

The goal is not simply to avoid a LEEP.

It is to understand whether avoiding excision is medically reasonable in your situation.

Sometimes the answer is yes.

Sometimes the safest recommendation is still an excisional procedure.

You should understand why before making that decision.

Who might consider imiquimod?

Imiquimod may be worth discussing if you:

  • Have biopsy-confirmed CIN2 or CIN3
  • Strongly prefer to avoid a LEEP or other excisional procedure
  • Are concerned about preserving cervical tissue for future pregnancy
  • Have a cervix and lesion that can be adequately evaluated
  • Understand that treatment may not work
  • Are comfortable with close follow-up
  • Understand that LEEP or another procedure may still be necessary

It is not appropriate when there is concern for invasive cervical cancer or when the cervix cannot be adequately evaluated.

CIN2 and CIN3 also carry different levels of risk, so the conversation is not identical for every patient.

The Evidence Behind Imiquimod

Imiquimod has been studied as a treatment for cervical dysplasia in randomized clinical trials and systematic reviews.

The results vary between studies and patient populations, but the evidence shows that imiquimod can produce regression of high-grade cervical dysplasia and may also promote clearance of high-risk HPV.

RANDOMIZED PLACEBO-CONTROLLED TRIAL
73% experienced regression
n a randomized trial of women with CIN2/3, 73% of women treated with imiquimod experienced regression to CIN1 or less, compared with 39% receiving placebo. The same study found high-risk HPV clearance in 60% of women treated with imiquimod compared with 14% receiving placebo.
IMIQUIMOD COMPARED WITH LEEP
Comparable results in a CIN2 subgroup
A randomized trial directly compared imiquimod with LLETZ/LEEP in women with high-grade cervical dysplasia. Among women with CIN2 p16+, treatment was successful in 73.9% with imiquimod and 84.2% with LLETZ. In this subgroup, the difference was not statistically significant. Results were less favorable for imiquimod in women with CIN3, reinforcing why the grade of dysplasia matters when considering treatment options.
SYSTEMATIC REVIEW & META-ANALYSIS
About 60% regression — and 60% HPV clearance
A 2024 systematic review and meta-analysis combined available studies of imiquimod for cervical dysplasia. Among women with CIN2/3, the pooled regression rate was 61%. Among women who completed imiquimod treatment, the pooled HPV clearance rate was 60%. The authors concluded that imiquimod was effective in reducing cervical intraepithelial neoplasia and promoting HPV clearance, while recognizing that excisional treatment remained more effective overall in the pooled population.

What does that mean for you?

The evidence does not suggest that every woman with CIN2 or CIN3 should choose imiquimod instead of LEEP.

It does show something important:

Imiquimod has a real treatment effect.

Some women experience regression of their cervical dysplasia, and some also clear the high-risk HPV infection associated with it.

Results differ considerably depending on the grade of dysplasia and the population being studied. For appropriately selected women—particularly those with CIN2 who strongly prefer to preserve cervical tissue—the published evidence makes imiquimod a reasonable option to discuss.

The question is not simply whether imiquimod or LEEP is “better.”

It is which approach makes the most sense for your disease, your cervix, your goals, and the level of risk you are comfortable accepting.

What Does Treatment Look Like?

Imiquimod treatment is a process, not a single procedure. We start by making sure it is a reasonable option for you, stay involved throughout treatment, and then carefully reassess the cervix afterward.

  • START WITH A COMPLETE EVALUATION

    Before recommending imiquimod, we review your Pap, HPV, biopsy, colposcopy, and previous treatment history and carefully evaluate the cervix. We need to understand not only what the pathology says, but where the abnormality is located and whether the cervix can be adequately evaluated.

  • TREATMENT OVER 16 WEEKS

    Treatment is gradually increased to improve tolerability. Our typical schedule begins once weekly, increases to twice weekly, and then progresses to three times weekly as tolerated. We remain involved throughout treatment rather than simply prescribing medication and waiting four months.

  • RE-EVALUATE THE CERVIX

    After treatment is completed and the cervix has had time to recover, we repeat the cervical evaluation. Follow-up may include colposcopy, HPV testing, cytology, and biopsy depending on your individual situation. Did the dysplasia regress — and what should happen next?

Imiquimod Treatment Program

$2,200

The program includes the initial cervical dysplasia consultation, evaluation for treatment, the 16-week treatment program, follow-up during therapy, management of treatment-related side effects, and post-treatment cervical reassessment.

Applicable pathology fees are additional.

You do not need to be a Hitchcock Family Medicine member.

Start with your results
Frequently Asked Questions
Is imiquimod FDA-approved for cervical dysplasia?
No. Imiquimod is an FDA-approved medication, but cervical dysplasia is not one of its labeled indications, so its use on the cervix is considered off-label. There is published clinical-trial and systematic-review evidence supporting its use in cervical dysplasia. It is not currently the standard U.S. guideline-based treatment for cervical HSIL, and we discuss that distinction as part of deciding whether it is reasonable in your situation.
How effective is imiquimod compared with LEEP?
Both imiquimod and LEEP can successfully treat cervical dysplasia, but the results vary depending on the patient population, the grade of dysplasia, and how treatment success is defined. This is why we don’t think of imiquimod simply as a “less effective LEEP.” It is a different treatment approach with different advantages and limitations. The important question is whether it offers a reasonable likelihood of success for you, given your grade of dysplasia, cervical findings, previous history, and treatment goals.
Does imiquimod help clear HPV?
Yes, it may. Imiquimod works by stimulating the local immune response, and clinical studies of cervical dysplasia have shown HPV clearance in a meaningful proportion of women following treatment. HPV clearance is not guaranteed, and our primary goal is to safely treat the cervical dysplasia rather than simply produce a negative HPV test. But the effect on HPV is one of the potential advantages of an immune-based treatment like imiquimod.
Can I consider imiquimod because I don’t want a LEEP?
Yes. Not wanting a LEEP is a completely reasonable reason to ask whether another option exists. It does not automatically make imiquimod appropriate. We still need to determine whether a nonsurgical approach can be considered safely based on your pathology, cervical examination and overall history.
What happens if it doesn’t work?
We reassess. Some women have complete regression, some have partial regression, and some have persistent high-grade dysplasia. If significant disease remains, we will discuss what should happen next. That may include further surveillance in selected circumstances or treatment with LEEP or another excisional procedure.
What are the side effects?
Because imiquimod stimulates an immune response, local irritation and systemic symptoms can occur. These may include vaginal or vulvar irritation, discharge, spotting, pelvic discomfort, fatigue, muscle aches, fever, chills or flu-like symptoms. Treatment can often be adjusted when side effects become difficult to tolerate.
Why might imiquimod matter if I want to become pregnant in the future?
LEEP is a highly effective treatment, but it works by removing a portion of the cervix. For many women, that is an entirely reasonable tradeoff. Imiquimod treats cervical dysplasia without removing cervical tissue. For a woman who hopes to become pregnant in the future, preserving cervical tissue may be an important consideration. Future pregnancy goals are absolutely part of the conversation when deciding which treatment approach makes the most sense.
Do I have to live in Chattanooga?
No. Women may travel to Chattanooga for cervical dysplasia evaluation and treatment. The initial evaluation is performed in person because determining whether imiquimod is appropriate requires an actual examination of the cervix.

Written and medically reviewed by Matthew Hitchcock, MD
Board-Certified Family Physician
Last reviewed: August 26, 2026

Colposcopy Second Opinion Imiquimod CIN2-3 Traveling

Have cervical dysplasia results and not sure what comes next?

You do not need to know exactly what kind of appointment or treatment you need before contacting us.

If you have an abnormal Pap or HPV result, need a colposcopy, have been diagnosed with CIN1, CIN2, or CIN3, have been told you may need a LEEP, or want a second opinion about your options, start with the results you already have.

Our team will review your request and help you understand the appropriate next step.

Get More Information